Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Inclusion Criteria: 1. Participant must be at least 18 years of age, at the time of signing the informed consent 2. Participants affected by Arrhythmogenic Cardiomyopathy as defined by task force criteria Exclusion Criteria: 1. Known hypersensitivity to atorvastatin or any of the excipients 2. Moderate or severe liver disease 3. Muscle disease 4. Left ventricular ejection fraction \<35% 5. Congestive heart failure defined by the New York Heart Association (NYHA) as class III or IV. 6. Known cardiomyopathy of other origin: post ischemic, hypertrophic, idiopathic dilated, restrictive; known moderate-to-severe mitral or aortic valvulopathy; pulmonary hypertension; congenital cardiac abnormalities 7. Hypercholesterolemic patients that require the use of lipid lowering drugs. 8. Heart transplantation 9. Estimated life expectancy of less than 2 years 10. Any other medical condition that, in the judgment of the investigator, places the patient at risk or makes the patient unreliable or limits the patient's ability to complete the study 11. Potent CYP3A4 modifiers such as Erythromycin, Clarithromycin Azole antifungals, Protease inhibitors , Gemfibrozil, Ciclosporin, Danazol 12. Fusidic acid (drug for bacterial infections) 13. Hepatitis C antivirals as telaprevir, boceprevir, glecaprevir/pibrentasvir and ledipasvir/sofosbuvir combination 14. Any other lipid lowering drugs such as Statins, Cholesterol absorption inhibitors, Bile acid sequestrants , PCSK9 inhibitors, Adenosine triphosphate-citrate lyase inhibitors , Fibrates, Omega-3 fatty acid ethyl esters 15. Drugs primary indicated as antioxidants 16. Enrollment in another clinical trial or past clinical trial in which an investigational drug was administered within 30 days of Visit 1 or within the 5 half-lives of the investigational drug, whichever is longer. 17. Pregnant or lactating women 18. Women of childbearing age who are not using adequate contraception 19. Known dependency on alcohol - drug abuse. 20. Contraindications to cardiac magnetic resonance